Ameritas Investment Partners
RARE icon

Ameritas Investment Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Ameritas Investment Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$293K Buy
+8,775
New +$218K 0.01% 1157
2021
Q2 		– Sell
-5,245
Closed -$597K – 3198
2021
Q1 		$597K Sell
5,245
-47
-0.9% -$6.4K 0.02% 739
2020
Q4 		$733K Buy
5,292
+391
+8% +$46.4K 0.03% 661
2020
Q3 		$403K Sell
4,901
-110
-2% -$9.12K 0.02% 771
2020
Q2 		$392K Buy
5,011
+157
+3% +$10.4K 0.02% 776
2020
Q1 		$216K Buy
4,854
+208
+4% +$10.8K 0.01% 896
2019
Q4 		$198K Hold
4,646
– – 0.01% 1093
2019
Q3 		$199K Hold
4,646
– – 0.01% 1055
2019
Q2 		$295K Buy
4,646
+293
+7% +$18.6K 0.01% 879
2019
Q1 		$302K Buy
4,353
+400
+10% +$22.9K 0.01% 865
2018
Q4 		$172K Hold
3,953
– – 0.01% 1045
2018
Q3 		$302K Hold
3,953
– – 0.01% 878
2018
Q2 		$304K Buy
3,953
+191
+5% +$12.3K 0.01% 864
2018
Q1 		$192K Buy
3,762
+288
+8% +$14.5K 0.01% 1096
2017
Q4 		$161K Hold
3,474
– – 0.01% 1210
2017
Q3 		$198K Hold
3,474
– – 0.01% 1070
2017
Q2 		$216K Buy
3,474
+248
+8% +$14.9K 0.01% 1022
2017
Q1 		$219K Buy
3,226
+115
+4% +$8.76K 0.01% 1007
2016
Q4 		$219K Hold
3,111
– – 0.01% 997
2016
Q3 		$221K Buy
+3,111
New +$199K 0.01% 965
2016
Q1 		– Sell
-3,021
Closed -$339K – 1184
2015
Q4 		$339K Hold
3,021
– – 0.02% 756
2015
Q3 		$291K Buy
3,021
+250
+9% +$28.6K 0.02% 781
2015
Q2 		$284K Buy
+2,771
New +$215K 0.02% 838

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Frontier Capital Management
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Ameritas Investment Partners's RARE Position: Q2 2026 in Review

Ameritas Investment Partners opened a new position in Ultragenyx Pharmaceutical (RARE) in Q2 2026: 8,775 shares worth $293K. The stake represents 0.01% of the portfolio and ranks #1157 among its holdings. This is a return to the name: Ameritas Investment Partners previously reported a position in RARE as recently as Q1 2021.

Ameritas Investment Partners first reported a position in RARE in Q2 2015 and has held it in 23 quarters since. The position peaked at $733K in Q4 2020. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Ameritas Investment Partners held 8,775 shares of Ultragenyx Pharmaceutical worth $293K as of Q2 2026.
  • Ultragenyx Pharmaceutical was a new Ameritas Investment Partners position in Q2 2026.
  • Ultragenyx Pharmaceutical made up 0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #1157 holding.
  • Ameritas Investment Partners first reported a position in Ultragenyx Pharmaceutical in Q2 2015 and has held it in 23 quarters since.
  • Ameritas Investment Partners's Ultragenyx Pharmaceutical position peaked at $733K in Q4 2020.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.